Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment

Breast cancer is very common syndrome and an important reason of cancer-related death among females around world. Although targeted treatments and chemotherapy have enhanced outcomes in specific subtypes, such as TNBC with less treatment possibilities and poor prognosis. Immunotherapy with (CAR)-T cells therapy showing useful progress in blood diseases; however, its application in breast cancer remains challenging. This study aimed to summarize the current progress, therapeutic potential and future directions of next-generation CAR-T cells treatment for BC. A comprehensive review of recent preclinical studies, clinical trials, and evolving approaches related to CAR-T cell treatment in BC was conducted. Google scholar, PubMed, Scopus, Web of Science, and Google was employed to retrieve the studies. CAR-T cell targeting breast cancer associated antigens such as MUC1, HER2, TROP2, GD2, ROR1, and EpCAM exhibit helpful antitumor activity. Mesothelin molecule expressed on different hard tumor cells surface is appropriate point for tumor cells with high MSLN expressions for CAR-T-cells treatment. Barriers limit clinical success, with tumor antigen heterogeneity, lack of tumor-specific targets, poor T-cell trafficking, functional exhaustion, and immunosuppressive TME. Safety concerns as tumor toxicity, high cost and difficulty to handle remain significant challenges. Emerging next-generation strategies with armored CAR-T cells, multi-target, logic-gated designs, cytokine-secreting constructs, gene editing, and combined treatment developed to overcome these limitations. Although CAR-T cells treatment is still in initial stages of clinical translation, ongoing advances in cellular engineering, target identification, and combination strategies hold significant promise for improving efficacy and safety. MSLN CAR-T-cells treatment, and other (iNKT), γδ T, and (MAIT) cells, play significant role in innate and adaptive immunity. Moreover, Allo 15MCAR-NKT cells as next-generation; off-the-shelf immunotherapy shows strong treatment potential for TNBC. Next-generation CAR-T approaches may provide transformative therapeutics with advanced and treatment-resistant breast cancer. In future there is need of next generation CARs to work more efficiently.

Authors

Institutions

Publication Details

Journal
Cancer Cell International
Published
2026-11-17
DOI
https://doi.org/10.1186/s12935-026-04500-2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment

Fouzia Tanvir, Yasir Nawaz, Basit Nawaz, Hafiza Fizzah Riaz
2 links
Cancer Cell International
CAR-T cell therapy research
article

Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment

Fouzia Tanvir, Yasir Nawaz, Basit Nawaz, Hafiza Fizzah Riaz
article en

Abstract

Breast cancer is very common syndrome and an important reason of cancer-related death among females around world. Although targeted treatments and chemotherapy have enhanced outcomes in specific subtypes, such as TNBC with less treatment possibilities and poor prognosis. Immunotherapy with (CAR)-T cells therapy showing useful progress in blood diseases; however, its application in breast cancer remains challenging. This study aimed to summarize the current progress, therapeutic potential and future directions of next-generation CAR-T cells treatment for BC. A comprehensive review of recent preclinical studies, clinical trials, and evolving approaches related to CAR-T cell treatment in BC was conducted. Google scholar, PubMed, Scopus, Web of Science, and Google was employed to retrieve the studies. CAR-T cell targeting breast cancer associated antigens such as MUC1, HER2, TROP2, GD2, ROR1, and EpCAM exhibit helpful antitumor activity. Mesothelin molecule expressed on different hard tumor cells surface is appropriate point for tumor cells with high MSLN expressions for CAR-T-cells treatment. Barriers limit clinical success, with tumor antigen heterogeneity, lack of tumor-specific targets, poor T-cell trafficking, functional exhaustion, and immunosuppressive TME. Safety concerns as tumor toxicity, high cost and difficulty to handle remain significant challenges. Emerging next-generation strategies with armored CAR-T cells, multi-target, logic-gated designs, cytokine-secreting constructs, gene editing, and combined treatment developed to overcome these limitations. Although CAR-T cells treatment is still in initial stages of clinical translation, ongoing advances in cellular engineering, target identification, and combination strategies hold significant promise for improving efficacy and safety. MSLN CAR-T-cells treatment, and other (iNKT), γδ T, and (MAIT) cells, play significant role in innate and adaptive immunity. Moreover, Allo 15MCAR-NKT cells as next-generation; off-the-shelf immunotherapy shows strong treatment potential for TNBC. Next-generation CAR-T approaches may provide transformative therapeutics with advanced and treatment-resistant breast cancer. In future there is need of next generation CARs to work more efficiently.

Cancer Cell International
Islamia University of Bahawalpur (PK), University of Okara (PK), University of Agriculture Faisalabad (PK)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon